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Abstract 
Few studies reported that androgens levels could be among the regulators of adipose tissue hormones. 
Polycystic ovary syndrome (PCOS) is characterized by both increased adiposity and hyperandrogenism, but the 
relationship between androgens levels and adipokines in PCOS has not been well characterized. Our aim was to 
study the relationship between leptin, adiponectin, total testosterone, sex hormone binding globulin (SHBG) and 
free androgen index (FAI) in PCOS patients. We conducted a cross-sectional study on 131 PCOS patients (mean 
age 24 [6] yrs, mean body mass index (BMI) 25.8 [10.44] kg/m2) diagnosed based on Rotterdam Consensus 
criteria. All the patients were evaluated by clinical, paraclinical and hormonal exam. HOMA-IR was calculated 
for all the patients. Leptin was positively associated with age (p<0.05), BMI (p<0,0001), waist-hip ratio (WHR) 
(p<0.0001), waist circumference (WC) (p<0,0001), HOMA-IR (p<0,0001), insulinemia (p<0.0001) and FAI 
(p<0,0001) and negatively with SHBG (p<0.0001). Adiponectin was negatively associated with age (p<0.05), 
BMI (p<0,0001), WC (p<0,0001), WHR (p<0,0001), HOMA-IR (p<0,0001), insulinemia (p<0.0001) and FAI 
(p<0,005) and positively associated with SHBG (p<0,0001). Both adipokines were not correlated with total 
testosterone. The association between serum leptin and FAI/SHBG was lost after adjustment for age and body 
mass index.  
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In turn the relationship between leptin and FAI, but not SHBG was independent of HOMA-IR. Circulating 
adiponectin was associated with SHBG independently of adiposity and HOMA-IR, but the association with FAI 
was lost after adjustment for HOMA-IR. In conlusion, circulating adipokines are correlated with FAI and SHBG 
serum levels. This association seems to be mediated by adiposity for leptin. Although the link between 
adiponectin and FAI is probably due to insulin resistance, SHBG seems to directly modulate adiponectin 
production. 
Keywords: polycystic ovary syndrome; adiponectin; leptin. 
1. Introduction  
Adipokines are proteic products of the adipose tissue with complex actions on the glucose and fat metabolism, 
energy balance, inflammatory response and reproductive function [1, 2]. Among the adipokines, leptin and 
adiponectin are the most extensively studied and their circulating levels were associated with the risk of diabetes 
melitus, ischemic stroke and myocardial infarction. Therefore it is belived that adipokines are potential 
mediators of the cardiometabolic complications associated with obesity. Regulators of adipose tissue hormones 
production remain incompletely understood, although few studies addressed this aspect and identified some 
possible modulators of adipocytes function, among them being sex hormones [3, 4]. A recent study in midlife 
women reported an inverse association between total testosterone level and circulating adiponectin independent 
of adiposity suggesting an independent effect of androgens on adiponectin production [5]. 
Polycystic ovary syndrome (PCOS) is the most frequent endocrinopathy of reproductive age women, affecting 
5-10 % of them and being characterized by hyperandrogenism and chronic oligoovulation. PCOS is not only a 
reproductive disorder, but also a disease which carries an increased risk for metabolic complications due to the 
insulin resistance found in most of these patients. Although insulin resistance is an intrinsic characteristic of the 
disease, the metabolic and reproductive phenotype could be aggravated by the presence of obesity especialy 
with central distribution, frequently found in these patients. Moreover PCOS patients seem to present also a 
dysfunction of the adipose tissue independently of adiposity distribution [6] the determinants of this dysfunction 
are not yet clarified. Although the androgens were previously suggested as possible regulators of adiposity 
function and hyperandrogenism is a central feature of PCOS, the relationship between circulating androgens and 
adipose tissue function was not well characterized in PCOS patients. Both adiponectin and leptin serum levels 
were demonstrated to accurately reflect the production in adipose tissue in PCOS patients, being an adequate 
marker of adiposity function [7]. Therefore the aim of our study was to analyze the  relationship between leptin, 
adiponectin and serum androgens levels in PCOS patients. 
2. Materials and Methods 
We performed a cross-sectional study which included 131 PCOS patients admitted in a tertiary care department 
between january 2007 and september 2011. All the patients gave the written informed consent before evaluation. 
The study was approved by the local Ethic Committee. Inclusion criteria were: no significant associated health 
condition, age between 18 and 40 yr. Exclusion criteria were: pregnancy in the last three months, lactating 
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women, current or recent treatment (in the last three months) with insulin sensitizing or combined oral 
contraceptives, postmenopausal status. PCOS diagnosis was based on the Rotterdam Consensus criteria [8] (the 
presence of two out of the following): oligo- or anovulation, clinical and/or biochemical hyperandrogenism and 
polycystic ovary appearance on transvaginal ultrasound, after exclusion of androgen producing tumours, 21-
hydroxilase deficiency, hypercorticism, thyroid dysfunction, hypogonadism and hyperprolactinemia.  
All the patients included in the study underwent a complet physical examination including weight, height, waist 
(WC) and hip circumferences (HC) measurements, determined to the nearest 0.1 kg and 0.1 cm, respectively. 
BMI was calculated by dividing the weight to the height squared (Kg/m2). Waist-hip ratio (WHR) was obtained 
as WC divided by HC.  Clinical hyperandrogenism, chronic ovulatory dysfunction were evaluated as previously 
described [9]. 
Blood samples were obtained at baseline and 2 hours after a standard oral glucose tolerance test (OGTT) in days 
3-5 of a spontaneous or progesterone-induced menstrual cycle, between 08:00 AM and 10:00 AM after a 12-h 
overnight fast. A pelvic ultrasonography was performed in the same day by an experienced operator in order to 
evaluate ovarian morfology. 
Total testosterone (TT), sex hormone binding globulin (SHBG), thyroid stimulating hormone (TSH), luteinizing 
hormone (LH), follicle stimulating hormone (FSH), estradiol, prolactin, adiponectin, leptin, glucose, insulin 
were measured from baseline serum samples in all subjects. Measurements of glucose and insulin fasting and 2h 
during oral glucose tolerance test (OGTT) were also performed in all patients not previously diagnosed with 
diabetes mellitus. Morning serum 17-hydroxiprogesterone and cortisol after an overnight suppression test were 
evaluated only in selected patients with a high clinical suspicion index.  
For the measurement of TT, SHBG, TSH, LH, FSH, estradiol, prolactin, cortisol, insulin, 17-
hydroxiprogesterone a chemiluminescent immunometric assay (Immulite 2000, Siemens Healthcare Diagnostics 
Products Ltd.) was used. Serum adiponectin and leptin levels were measured with an ELISA kit (DRG 
Instruments, Germany).  
The homeostasis model assessment of insulin resistance (HOMA-IR) and free androgen index (FAI) were 
calculated as already described [9]. Biochemical hyperandrogenism was defined as an elevation of total 
testosterone ≥ 0.73 ng/mL and / or of FAI ≥ 4.5 [9]. 
Statistical analysis was performed using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA). Data are expressed 
as median and interquartile range. Variables non-normaly distributed were logtransformed before submission to 
multiple regression analysis. In all performed statistical procedures, P values < 0.05 were considered statistically 
significant.  
3. Results 
A total number of 131 PCOS patients were included in the study with a median age of 24 years and median BMI 
of 25.8 kg/m2 (table 1). 
370 
 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2014) Volume 15, No  2, pp 368-378 
Table 1. Clinical and paraclinical parameters of the study group 
Parameter Median [interquartile range] 
Age (yrs) 24 [6] 
BMI (kg/m2) 25.8 [10.44] 
WHR 0.82 [0.11] 
WC (cm) 82 [25.31] 
HOMA-IR 2.42 [2.98] 
Fasting insulin (µUI/mL) 11.45 [14.2] 
2h insulin (µUI/mL) 61.2 [76.45] 
Total testosteron (ng/ml) 0.75 [0.45] 
SHBG (nmol/L) 36.6 [31.1] 
FAI 6.91 [8.17] 
Adiponectin (mg/L) 8.81 [6.38] 
Leptin (ng/ml) 20 [25.9] 
 
Table 2. Correlation between serum adiponectin levels and clinical and paraclinical parameters (Spearman 
analysis was applied. r: correlation coefficient between serum adiponectin and variate parameters found in the 
first column; NS: not-significant). 
Parameter r p 
Age (yrs) -0.191 0.029 
BMI (kg/m2) -0.526 <0.0001 
WHR -0.551 <0.0001 
WC (cm) -0.566 <0.0001 
HOMA-IR -0.452 <0.0001 
Fasting insulin (µUI/mL) -0.451 <0.0001 
2h insulin (µUI/mL) -0.321 <0.0001 
Total testosteron (ng/ml) 0.040 NS 
SHBG (nmol/L) 0.363 <0.0001 
FAI -0.285 0.002 
leptin(ng/ml) -0.329 <0.0001 
 
 
Using Spearman correlation test we found that serum adiponectin level was significantly and negatively 
correlated with age, anthropometrical indices of adiposity (BMI, WC and WHR), fasting and 2h insulinemia, 
HOMA-IR index and FAI and positively with SHBG (table 2). Serum leptin level was positively correlated with 
age, BMI, WC, WHR, HOMA-IR, fasting and 2h insulinemia, FAI and negatively with SHBG (table 3). We 
also found a negativ correlation between serum levels of leptin and adiponectin (table 3). On the other hand 
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neither circulating leptin or adiponectin were correlated with total testosteron (table 2 and table 3). From the 
clinical and biochemical parameters analyzed, serum leptin level was strongest correlated with BMI (r= -0.779, 
p< 0.0001) and serum adiponectin level was strongest correlated with WC (r= -0.566, p< 0.0001). 
Table 3. Correlation between serum leptin levels and clinical and paraclinical parameters (Spearman analysis 
was applied. r: correlation coefficient between serum leptin and variate parameters found in the first column; 
NS: not-significant). 
Parameter r p 
Age (yrs) 0.218 0.014 
BMI (kg/m2) 0.779 <0.0001 
WHR 0.461 <0.0001 
WC (cm) 0.736 <0.0001 
HOMA-IR 0.658 <0.0001 
Fasting insulin (µUI/mL) 0.618 <0.0001 
2h insulin (µUI/mL) 0.524 <0.0001 
Total testosteron (ng/ml) 0.161 NS 
SHBG (nmol/L) 0.400 <0.0001 
FAI -0.391 <0.0001 
Adiponectin (mg/L) -0.329 <0.0001 
 
Standard multivariate linear regression analyzis showed that, after adjustment for BMI and age, FAI and SHBG 
were no longer significantly associated with serum leptin levels. In these models BMI was the only independent 
predictor of serum leptin level (beta = 0.699, p < 0.0001 in the model including FAI; beta= 0.700, p < 0.0001 in 
the model with SHBG). In two models of multiple linear regression including leptin as dependent variable and 
age, HOMA-IR and FAI or SHBG as independent variables, age (beta = 0.183, p = 0.019 in the model with FAI, 
beta = 0.181, p = 0.023 in the model with SHBG), HOMA-IR (beta= 0.522, p < 0.0001 in the model with FAI, 
beta = 0.561, p < 0.0001 in the model with SHBG) and FAI (beta = 0.187, p = 0.023, but not SHBG were 
independent predictors of serum leptin.  
Serum adiponectin were independentely associated with both FAI (beta = - 0.206, p = 0.026) and SHBG (beta = 
0.260, p = 0.006) after adjustment for age and WHR. In these models WHR was the strongest independent 
predictor of circulating adiponectin (beta = -0.423, p < 0.0001 in the model with FAI, beta = - 0.393, p < 0.0001 
in the model with SHBG), but age was no longer independently associated with adiponectin after adjustment for 
confounders. On the other hand, analyzing the influence of FAI / SHBG on adiponectin serum level taking into 
account the insulin resistance we observed that age (beta = - 0.195, p < 0.032 in the model with FAI, beta = - 
0.215, p < 0.016 in the model with SHBG), HOMA-IR (beta = - 0.356, p < 0.001 in the model with FAI, beta = 
- 0.321, p < 0.001 in the model with SHBG) and SHBG (beta = 0.250, p < 0.01) were independently associated 
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with circulating adiponectin. Instead FAI was not significantly associated with adiponectin in this model 
containing HOMA-IR.  
4. Discussions 
Our study showed that in PCOS patients there is an association between the serum levels of adipokines (leptin 
and adiponectin) and androgenic status (reflected by circulating FAI and SHBG). Although our data suggest a 
link between both FAI and SHBG and adipose tissue function (reflected by circulating adipokines levels), it is 
difficult to demonstrate a causal relationship due to the cross-sectional design of our study. Moreover the data 
available from the literature support a bidirectional relationship, probably closing a vicious circle. Thus 
circulating adipokines are closely related to the adiposity quantity and increase in adiposity, in particular the 
abdominal type, is associated with insulin resistance and hyperinsulinemia which determine the suppression of 
hepatic SHBG production and increases the ovarian androgen synthesis through enhancement of LH-mediated 
steroidogenesis in the theca cells [10], providing a possible explanation for the association between adiposity 
function and FAI/SHBG. Thus a first hypothesis which would explain the association between circulating 
adipokines and FAI/SHBG is that the relationship is due to the capacity of adiposity to modulate androgens 
production and bioavailability. Therefore the two parameters are associated because both similarly reflect the 
adiposity quantity and function. 
Conversely, androgens are generally viewed as able to significantly influence the adipocyte function and the 
distribution of body fat in women [11], favoring visceral adiposity [12]. However, most of the evidences come 
from the clinical studies showing a positive association between serum testosterone values and abdominal 
adiposity in patients with or without hyperandrogenism [13, 14]. Actually, the results of the clinical studies are 
heterogeneous, not all of them confirming this association. Even more confusing, experimental studies showed 
an inhibitory effect of the androgens on the differentiation of subcutaneous preadipocytes in mature adipocytes 
[15]. However in visceral adipose tissue testosterone exerts a proliferative effect on preadipocytes [16]. 
Therefore testosterone seems to increase visceral adiposity without a major influence on subcutaneous adiposity. 
Thus this capacity of testosterone to modulate adiposity distribution could be another explanation for the 
relationship between adipokines and androgenic status. However the possibility that androgens to influence the 
adipose tissue function without influencing the adiposity quantity should not be neglected as few studies 
demonstrated the capacity of androgens to modulate some aspects of adipose tissue function [17].    
A third hypothesis for the mechanisms underlying the association between circulating adipokines and FAI is the 
capacity of adipokines to modulate the androgen production since the receptors of both leptin and adiponectin 
were identified in the ovary. However, experimental studies showed that leptin inhibited the androstendione 
production by internal theca cells and adiponectin had synergistic effect with insulin and IGF-I in theca cells 
[10]. These effects are opposite to the observed association in our study, suggesting that the direct action of 
adipokines on the ovary is not a pivotal mechanism.  
In order to shed some light on the relationship between androgens and adipokines serum levels in our PCOS 
patients we analyzed the association taking into account adiposity and insulin resistance. Although in bivariate 
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analysis serum leptin levels were correlated with FAI and SHBG, after adjustment for BMI and age this 
relationship was no longer significant, suggesting that the association is rather due to the effect of adiposity on 
FAI and SHBG. However a modulator effect of androgens or SHBG on adipose tissue function could not be 
excluded since the receptors for both SHBG and androgens were found on adipocytes [18]. Moreover the 
testosterone administration was showned to influence adipokines production in hypogonadal men [19, 20], 
although similar data are not available for women.  
The strong relationship between global adiposity reflected by BMI and leptin serum level suggested by the 
bivariate analysis was also supported by the fact that BMI was the only independent predictor of serum leptin 
level in multivariate regression model including also age and FAI/SHBG. This finding suggests that global 
adiposity is the most significant regulator of circulating leptin in our patients. Indeed this association is in 
accord with the physiological role of leptin to regulate the fat mass and body weight, therefore its production 
reflecting the fat stores of the body. This aspect is confirmed by the results of few experimental studies, most of 
them on normal ovulatory women, showing that leptin expression is increased in overweight and obese women 
predominantly by increased production in subcutaneous adipose tissue [21]. Subcutaneous adiposity is 
quantitatively the most important compartment of the total adipose tissue being best reflected by BMI, therefore 
explaining the close correlation between BMI and serum leptin.   
Although the mechanism is not completely clarified, leptin seems to be associated with insulin resistance as 
showned by the data from the ob/ob mice and from the patients with human immunodeficiency virus infection 
and lipoatrophy secondary to antiretroviral therapy. On the other hand, the results of the clinical studies are 
heterogeneous, some [22], but not all studies confirming this association [23]. In our patients circulating leptin 
was significantly correlated with both HOMA-IR and insulinemia (fasting and 2h during oral glucose tolerance 
test). This association was independent of age and androgenic status. In turn, after adjustment for adiposity 
(BMI) the relationship between serum leptin and insulin resistance was no longer statisticaly significant (data 
not shown), suggesting that adiposity is an important mediator of this connection, probably by strongly 
influencing both parameters.  
Insulin resistance is one of the factors contributing to hyperandrogenism in PCOS, therefore being a possible 
confounder when analyzing the relationship between leptin and androgens. However, the link between leptin 
and FAI seems to be independent of insulin resistance as showned in multiple regression analyzis. On the other 
hand SHBG was not associated with leptin serum levels independently of insulin resistance, suggesting a 
stronger influence of insulin resistance on serum SHBG in comparison to FAI.  
In our study group serum adiponectin level was negatively correlated with FAI and their relationship was 
independent of adiposity. Therefore, although the adiposity could  influence both adiponectin and bioavailable 
testosterone, this is not entirely responsible for the association of the two parameters. Probably our results are 
due to the androgens capacity to influence the adipose tissue function reflected by adiponectin independently of 
adipose tissue quantity. Although the effect of androgens to modulate leptin production by the adipose tissue 
was reported in men, the same aspect in women was less addressed in previous studies. One experimental report 
suggested that the adiponectin secretion is not influenced by sex hormones [24], although the effect could 
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variate according to gender, adipocytes type and hormonal interactions [25]. However few studies evaluated this 
aspect and future research is necessary to clarify this aspect.  
Adiponectin is strongly and negatively associated with insulin resistance in many previous studies, probably due 
to the insulin sensityzing effect of adiponectin, but also to the fact that the most insulin resistant adipocytes are 
those secreting less adiponectin [26]. Insulin resistance and the resulting hyperinsulinemia is also one of the 
main regulator of hyperandrogenism in PCOS. The relationship between insulin resistance and both adiponectin 
and FAI seems to be responsible for the observed link between  adiponectin and hyperandrogenism in our study 
group.   
On the other hand serum level of SHBG was associated with circulating adiponectin independent of age, 
adiposity and insulin resistance, suggesting a direct effect of SHBG on adipose tissue function in PCOS patients. 
Strong evidences regarding this aspect are lacking, but the SHBG receptors are present on the adipocytes and 
SHBG is an independent risk factor for metabolic syndrome and diabetes mellitus [27, 28], supporting our 
hypothesis.  
However in these models WHR was the most significant independent predictor of circulating adiponectin level, 
demonstrating the major role of central adiposity in regulation of serum adiponectin level. Indeed in vitro 
studies suggest that adiponectin production is inversely proportional to visceral adiposity and may be 
determined primarily by adipocyte size and insulin sensitivity, with larger, insulin-resistant adipocytes 
producing less adiponectin [26]. 
Plasma levels of both adiponectin and leptin were previously showned to be correlated with age [26] and this 
was true in our patients as well. However the association was lost after adjustment for adiposity parameters, 
suggesting that probably increase in adiposity with age is the responsible mechanism.   
Our study has limitations, one of them being the cross-sectional design which does not allow us to confirm a 
causal relationship between adipose tissue dysfunction and androgenic status in our patients. Another limitation 
is the lack of a complete profile of circulating androgens in the present study since they may have a different 
relationship with the adiposity. 
5. Conclusions 
Our study showed that both adipokines were related to FAI and serum levels of SHBG, although the relationship 
seems to be differently modulated by adiposity and insulin resistance. Thus, the link between leptin and 
FAI/SHBG appears to be modulated by global adiposity. In turn the relationship between adiponectin and FAI 
are rather due to insulin resistance with a minor contribution of the central adiposity. However the link between 
adiponectin and SHBG seems to be independent of confounders like adiposity, insulin resistance and age. In 
order to gain further knowledge regarding the link between adiposity dysfunction and androgens in PCOS 
patients future interventional studies are necessary. 
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